share_log

C4 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Adams Kendra

SEC announcement ·  Mar 8 19:26
Summary by Moomoo AI
Kendra Adams, the Chief Financial Officer of C4 Therapeutics, Inc. (CCCC.US), was reported to have engaged in a transaction involving the company's stock on March 7, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action type and status of the transaction were also not provided. Investors are advised to await further disclosures for more comprehensive details regarding the transaction.
Kendra Adams, the Chief Financial Officer of C4 Therapeutics, Inc. (CCCC.US), was reported to have engaged in a transaction involving the company's stock on March 7, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action type and status of the transaction were also not provided. Investors are advised to await further disclosures for more comprehensive details regarding the transaction.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more